Adlai Nortye Ltd. American Depositary Shares (ANL) - Total Assets
Based on the latest financial reports, Adlai Nortye Ltd. American Depositary Shares (ANL) holds total assets worth $34.43 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Adlai Nortye Ltd. American Depositary Sh (ANL) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Adlai Nortye Ltd. American Depositary Shares - Total Assets Trend (2019–2025)
This chart illustrates how Adlai Nortye Ltd. American Depositary Shares's total assets have evolved over time, based on quarterly financial data. See Adlai Nortye Ltd. American Depositary Sh shareholders equity for net asset value and shareholders' equity analysis.
Adlai Nortye Ltd. American Depositary Shares - Asset Composition Analysis
Current Asset Composition (December 2025)
Adlai Nortye Ltd. American Depositary Shares's total assets of $34.43 Million consist of 78.1% current assets and 21.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 69.1% |
| Accounts Receivable | $1.39 Million | 4.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $19.00K | 0.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Adlai Nortye Ltd. American Depositary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Adlai Nortye Ltd. American Depositary Sh.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Adlai Nortye Ltd. American Depositary Shares's current assets represent 78.1% of total assets in 2025, an increase from 59.5% in 2019.
- Cash Position: Cash and equivalents constituted 69.1% of total assets in 2025, up from 55.7% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 4.0% of total assets.
Adlai Nortye Ltd. American Depositary Shares Competitors by Total Assets
Key competitors of Adlai Nortye Ltd. American Depositary Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Cidara Therapeutics Inc
NASDAQ:CDTX
|
USA | $518.65 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Genscript Biotech Corporation
F:G51
|
Germany | €4.85 Billion |
|
Pharming Group NV
NASDAQ:PHAR
|
USA | $489.37 Million |
|
Guangzhou Boji Medical and Biotechnological Co Ltd
SHE:300404
|
China | CN¥1.67 Billion |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098
|
China | CN¥1.53 Billion |
Adlai Nortye Ltd. American Depositary Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.65 | 1.41 | 0.21 |
| Quick Ratio | 0.65 | 1.41 | 0.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-14.74 Million | $18.70 Million | $-246.35 Million |
Adlai Nortye Ltd. American Depositary Shares - Advanced Valuation Insights
This section examines the relationship between Adlai Nortye Ltd. American Depositary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 82.76 |
| Latest Market Cap to Assets Ratio | 21.32 |
| Asset Growth Rate (YoY) | -51.7% |
| Total Assets | $34.43 Million |
| Market Capitalization | $734.18 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Adlai Nortye Ltd. American Depositary Shares's assets at a significant premium (21.32x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Adlai Nortye Ltd. American Depositary Shares's assets decreased by 51.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Adlai Nortye Ltd. American Depositary Shares (2019–2025)
The table below shows the annual total assets of Adlai Nortye Ltd. American Depositary Shares from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $34.43 Million | -51.69% |
| 2024-12-31 | $71.27 Million | -45.26% |
| 2023-12-31 | $130.19 Million | +79.34% |
| 2022-12-31 | $72.59 Million | -44.87% |
| 2021-12-31 | $131.69 Million | +258.40% |
| 2020-12-31 | $36.74 Million | +240.10% |
| 2019-12-31 | $10.80 Million | -- |
About Adlai Nortye Ltd. American Depositary Shares
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rect… Read more